Skip to main content
padlock icon - secure page this page is secure

Dofetilide-Induced Long QT and Torsades de Pointes

Buy Article:

$52.00 + tax (Refund Policy)

Dofetilide, a new class III antiarrhythmic agent, has been approved as an antiarrhythmic agent for the treatment of atrial fibrillation and atrial flutter. Dofetilide selectively inhibits the rapid component of the delayed rectifier potassium current resulting in a prolongation of the effective refractory period. Like other drugs that affect potassium currents, the prolonged QT interval occurring in the patients treated with dofetilide can be complicated by torsades de pointes. We report four cases of dofetilide-induced QT prolongation and torsades de pointes. We discuss the risk factors for the development of dofetilide-induced long QT and torsades de pointes and review the current literature.

A.N.E. 2007;12(3):197–202s
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Tikosyn; atrial fibrillation; dofetilide; torsades de pointes

Document Type: Research Article

Affiliations: 1: University of Rochester, Strong Memorial Hospital, Department of Cardiovascular Diseases, Rochester, NY 2: Formerly Professor of Medicine (Cardiology), Director of Heart Station, University of Rochester. Currently Co-director, Cardiovascular Sciences, Covance, Reno, Nevada

Publication date: July 1, 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more